more_reports

The Latest Life Sciences Tools & Diagnostics Articles from Streetwise Reports

Is This AI Healthcare Stock Worth Being Overweight On?

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) is a Strong Buy and worth being overweight on.
Tags: Healthcare ServicesTechnologyLife Sciences Tools & Diagnostics

Healthcare Tech Firm and Leading University to Join Forces

  ()
The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform.
Tags: Life Sciences Tools & DiagnosticsTechnology

AI Healthcare Co. Signs Partnership With Large Regional Health Plan

Research Report
  ()
Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note.
Tags: Life Sciences Tools & DiagnosticsHealthcare ServicesTechnology

AI Healthcare Co. Creates AI Pharmacy Assistant

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource."
Tags: Life Sciences Tools & Diagnostics

AI Health Stock Heading Higher Expert Says

Contributed Opinion
  ()
Technical Analyst Clive Maund gives an update on Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) as he believes "something is going on" and the stock may be heading higher.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & DiagnosticsTechnology

Co. Expands Telehealth Contract to New State

  ()
Reliq Health Technologies Inc. announced that a large U.S. health group has expanded its contract with the telehealth company to cover facilities in a new state. Read why one analyst thinks the stock is a Buy.
Tags: Healthcare ServicesMedical DevicesLife Sciences Tools & Diagnostics

Showing Results: 1 to 6 of 6